Tag Archives: Lung cancer

Bio-Techne have researchers published a validation study demonstrating that the proprietary exosome-based liquid biopsy tests from Bio-Techne’s Exosome Diagnostics brand may be used to assess the...

Epidemiological studies have illustrated that regular aspirin consumption may decrease the risk of non-small cell lung cancer (NSCLC). Zhujiang Hospital researchers investigated the mechanism of aspirin-induced inhibition of NSCLC development during hypoxia. A549 cells were pre-treated with the vehicle control ...

Tumor-derived exosomes are gaining attention as important factors that facilitate communication between neighboring cells and manipulate cellular processes associated with cancer development or...

Exposure to nanoparticles may lead to pneumoconiosis and lung cancer; however, whether patients suffering from pneumoconiosis also face a...

Extensive research in genetics and genomics has revealed that lung cancer is a physiologically complex and genetically heterogeneous disease. Although molecular targets that can yield favorable response...

Molecularly targeted therapies and immune checkpoint inhibitors have markedly improved the therapeutic management of advanced lung cancer. However, it still remains the leading cause of cancer-related mortality worldwide, with disease stage at diagnosis representing the main prognostic factor. Detection of ...

Liquid biopsy is a non-invasive substitute to surgical biopsies for the detection of molecular biomarkers. Liquid biopsy forms an integral part of precision...

Integrated Diagnostics today announced the e-publication of full results of a large prospective clinical trial validating its Xpresys Lung 2® in the peer-reviewed medical journal CHEST, the official journal of the American College of Chest Physicians, titled: Assessment of Plasma Proteomics ...

The therapeutic landscape of lung cancer has expanded significantly over the past decade. Advancements in molecularly targeted therapies, strategies to discover and treat resistance mutations, and development of personalized cancer treatments in the context of tumor heterogeneity and dynamic tumor ...

InVision™ ctDNA liquid biopsy platform to be used to inform therapy following surgery of curative intent Addario Lung Cancer Medical Research Institute (ALCMI), a patient-founded not-for-profit global research consortium, and Inivata, a global clinical cancer genomics company utilizing an industry-leading liquid ...